Danish pharmaceutical giant Novo Nordisk has launched yet another much-anticipated weight loss drug, namely, Wegovy, into the Indian markets. The drug is priced at ₹17,345 for the monthly course. Established as another key development in India's obesity drive, the country is increasingly burdened by health issues caused by sedentary lifestyles and dietary changes.
Wegovy: It is an injectable prescription drug initially invented for treating diabetes mellitus type 2. After being approved in several countries, such as the U.S., UK, and EU to be marketed for obesity control, it has now been given the green light for manufacture and marketing by Indian regulatory bodies.
The spokesperson for Novo Nordisk India confirmed that Wegovy will be available in selected cities beginning this month. "This is a landmark time for India in its approach to obesity as a chronic disease requiring long-term management. We are committed to supporting patients with proven science and access," the company said in a statement.
Wegovy is intended for adults with a body mass index (BMI) of 30 or higher, or 27 and above if they have at least one weight-related health condition such as hypertension or type 2 diabetes. The drug is administered via a once-weekly injection and is part of a holistic plan that includes dietary modifications and physical activity.
Obesity among Indian adults has almost doubled over the past two decades—NFHS-5 (National Family Health Survey). The urban population is especially hit, with higher incidences of metabolic disorders like diabetes, fatty liver, and cardiovascular ailments being directly linked to obesity.
The introduction of Wegovy in India could provide new hope for millions besieged by weight-loss problems. But the pricing raises questions about accessibility. At ₹17,345 a month, the drug would probably be unaffordable for many in India unless its costs are defrayed under insurance or government health programs.
Dr. Prashant Mehta, an endocrinologist practicing in Mumbai, said that while he welcomed the availability of the drug, careful screening would be required. He added, "Semaglutide has shown phenomenal results in trials worldwide, with patients losing 15-20% of body weight. But it's not a silver bullet. It has to be within a supervised plan with proper monitoring."
The demand for Wegovy in the U.S. has surged to such an extent that Novo Nordisk faced ever-increasing supply shortages in 2023 and 2024. Following this, the company increased production and expanded its facilities worldwide to meet demand requirements. India is a major new market with long-term growth potential, especially among urban, health-conscious consumers.
With the launch of Wegovy, the company strengthens its presence in the growing chronic care space in India. As weight management becomes a form of medical treatment, the drug will trigger further discussions around the equity of healthcare systems, pricing, and the role of lifestyle drugs in public health.